115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • METxMET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
    Meeting Abstract

    Cho, B. C.; Ahn, M. J.; Kim, T. M.; Kim, S. W.; Han, J. Y.; Kim, C.; Shim, B.; Ricordel, C.; Drilon, A. E.; Pujol, J. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC
    Meeting Abstract

    Krebs, M. G.; Lu, S.; Fan, Y.; Yu, Y.; Drilon, A. E.; Siena, S.; Xue, C.; Bradley, D.; Hu, X.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial
    Meeting Abstract

    Solomon, B. J.; Drilon, A. E.; Wirth, L. J.; Szpurka, A.; Rao, X.; Massey, A. C.; Barker, S.; Wright, J.; Won, H.; Cabanillas, M. E.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab
    Meeting Abstract

    Passaro, A.; Yu, H. A.; Nguyen, D.; Lee, V. H. F.; Soo, R. A.; Kim, S. H.; Daga, H.; Tan, D. S. W.; Kim, S. W.; Juan Vidal, O. J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours
    Meeting Abstract

    Drilon, A. E.; Lin, J. J.; Johnson, M. L.; Baik, C. S.; Paz-Ares, L. G.; Besse, B.; Mazieres, J.; Swalduz, A.; Minchom, A. R.; Reuss, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
    Meeting Abstract

    Besse, B.; Drilon, A. E.; Cho, B. C.; Camidge, D. R.; Neal, J.; Lin, C. C.; Liu, S. V.; Nagasaka, M.; Kao, S. C. H.; Felip, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
    Meeting Abstract

    Chan, J.; Geyer, S.; Zemla, T.; Knopp, M. V.; Behr, S. C.; Pulsipher, S.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159
    Meeting Abstract

    Reuss, J.; Leung, C. H.; Rosner, S.; Zhou, N.; Weissferdt, A.; Pataer, A.; Nassib William, W. Jr; Taube, J.; Broderick, S.; Spicer, J. D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Impact of multicancer early detection (MCED) test on participant-reported outcomes (PRO) and behavioral intentions by cancer risk
    Meeting Abstract

    Dilaveri, C. A.; McDonnell, C. H. 3rd; Klein, E. A.; Reid, R.; Marinac, C. R.; Nadauld, L.; Chung, K. C.; Lopatin, M.; Fung, E. T.; Schrag, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Modeled economic and clinical impact of a multi-cancer early detection (MCED) test in a population with hereditary cancer syndromes
    Meeting Abstract

    Raoof, S.; Tafazzoli, A.; Kansal, A.; Shaul, A.; Ye, W.; Fendrick, M.
    Annals of Oncology (2024)

    Fulltext@MSK | Save